Medtech M&A: The industry’s biggest mergers and acquisitions of 2021

[Image from Jp Valery on Unsplash]

Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.

Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.

Here are the 10 biggest mergers and acquisitions in medtech in 2021:


Read more
  • 0

PerkinElmer completes $5.25B acquisition of BioLegend

PerkinElmer (NYSE:PKI) announced that it completed its acquisition of BioLegend for approximately $5.25 billion.

Waltham, Mass.-based PerkinElmer looks to use the acquisition — the largest in the company’s history — to expand its life science franchise into high-growth areas including cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing.

The company in July announced the acquisition of the antibody and reagent developer for approximately $5.25 billion in a combination of cash and stock.

“BioLegend’s stellar leaders, teams and technologies will play a critical role in our combined companies’ ability to provide new, innovative solutions to scientists — helping drive novel therapeutic discovery and development,” PerkinElmer president & CEO Prahlad Singh said in a news release. “We also look forward to BioLegend significantly enhancing our leading reagents portfolio as we pa…

Read more
  • 0

PerkinElmer announces Street-beating Q2, plans to acquire BioLegend for $5.3B

PerkinElmer (NYSE:PKI) today posted Street-beating second-quarter revenues and announced the $5.3 billion acquisition of BioLegend.

The Waltham, Mass.-based company posted profits of $245.9 million, or $2.19 per share, on sales of $1.2 billion for the three months ended July 4, 2021, for a 79.3% bottom-line gain on sales growth of 51.3%.

Adjusted to exclude one-time items, earnings per share were $2.83, 42¢ ahead of Wall Street, where analysts were looking for sales of $1.1 billion. PerkinElmer projected its full-year revenue to total $4.57 billion with adjusted EPS coming in at $9.88 per share.

The company also announced the acquisition of antibody and reagent developer BioLegend for approximately $5.25 billion in a combination of cash and stock.

“The organization continues to perform extremely well through the first half of 2021. Underpinned by the strategic pillars we highlighted at our recent Analyst Day and now the exciting addition of BioLeg…

Read more
  • 0